drugset / Trial / NCT02554318

Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia

NCT02554318

RandomizedParallel-groupOpen-labelSupportive care

Summary

Tuberculosis (TB) patients often have a lower body mass index (BMI) and experience wasting. Wasting reduces lean body mass and may cause physical function impairment. This study aimed to determine the efficacy of fermented soybeans (tempeh) as a food supplement on body weight and physical function changes among active pulmonary tuberculosis patients with standard therapy.

Timeline

Start
2013-11
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Background Ethambutol Small molecule 550 mg Oral
Background Ethambutol Small molecule 825 mg Oral
Background Ethambutol Small molecule 1100 mg Oral
Background Ethambutol Small molecule 1375 mg Oral
Background Isoniazid Small molecule 150 mg Oral
Background Isoniazid Small molecule 225 mg Oral
Background Isoniazid Small molecule 300 mg Oral
Background Isoniazid Small molecule 375 mg Oral
Background Pyrazinamide Small molecule 800 mg Oral
Background Pyrazinamide Small molecule 1200 mg Oral
Background Pyrazinamide Small molecule 1600 mg Oral
Background Pyrazinamide Small molecule 2000 mg Oral
Background Rifampin Small molecule 300 mg Oral
Background Rifampin Small molecule 450 mg Oral
Background Rifampin Small molecule 600 mg Oral
Background Rifampin Small molecule 750 mg Oral